Richard qualified in medicine at St Mary's Hospital Medical School, now Imperial College in London. After several posts in the NHS, he joined Pfizer as a medical advisor responsible for rheumatology and infection. After obtaining an MBA from Kingston Business School, he set up the Outcomes Research Group at Pfizer. In 1999, he founded the Goffin Consultancy to provide evidence-based health economics and data review for the healthcare industry. With over 30 years' experience in the pharmaceutical industry, his clients have ranged from start-ups to blue chip pharmaceutical companies as well as OTC companies, medical device companies and private equity houses wanting to review potential investment opportunities.   Richard has worked in the medical and economic aspects of Alzheimer's disease and drugs in mental health both while at Pfizer and later as a consultant. In addition, he has worked in a variety of conditions including infection, cardiovascular disease, gastrointestinal disease, cancer and arthritis   He brings a wide background in clinical studies, economic analyses and meta-analyses following over 30 years in the pharmaceutical industry as well as wide experience in presenting clinical and health economic studies both in print, at symposia and for training purposes. He has worked with several companies in the medical affairs, health technology assessment, pricing and reimbursement and market access fields. He is the author of numerous market, data and literature reviews and core-value documents as well as several publications Richard qualified in medicine at St Mary's Hospital Medical School, now Imperial College in London. After several posts in the NHS, he joined Pfizer as a medical advisor responsible for rheumatology and infection. After obtaining an MBA from Kingston Business School, he set up the Outcomes Research Group at Pfizer. In 1999, he founded the Goffin Consultancy to provide evidence-based health economics and data review for the healthcare industry. With over 30 years' experience in the pharmaceutical industry, his clients have ranged from start-ups to blue chip pharmaceutical companies as well as OTC companies, medical device companies and private equity houses wanting to review potential investment opportunities.   Richard has worked in the medical and economic aspects of Alzheimer's disease and drugs in mental health both while at Pfizer and later as a consultant. In addition, he has worked in a variety of conditions including infection, cardiovascular disease, gastrointestinal disease, cancer and arthritis   He brings a wide background in clinical studies, economic analyses and meta-analyses following over 30 years in the pharmaceutical industry as well as wide experience in presenting clinical and health economic studies both in print, at symposia and for training purposes. He has worked with several companies in the medical affairs, health technology assessment, pricing and reimbursement and market access fields. He is the author of numerous market, data and literature reviews and core-value documents as well as several publications

fermentation